Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada.
Frequently asked questions
What sector does Revive Therapeutics Ltd (RVV) operate in?
Revive Therapeutics Ltd belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Revive Therapeutics Ltd (RVV) current stock price?
As of the latest data, Revive Therapeutics Ltd stock price is CA$0.02, with a previous close of CA$0.02.
What is Revive Therapeutics Ltd (RVV) current market capitalization?
Revive Therapeutics Ltd market cap is approximately 8.71 million.
What is Revive Therapeutics Ltd (RVV) Earnings Per Share (EPS)?
The trailing EPS is -CA$0.03.
Does Revive Therapeutics Ltd (RVV) pay dividends?
No. Revive Therapeutics Ltd does not pay a dividend.
What is Revive Therapeutics Ltd (RVV) beta (volatility) score?
Revive Therapeutics Ltd has a beta of -1.791, indicating lower volatility than the overall market.